Layoff file: Thermo Fisher, and why you cannot find PPD in the numbers

Thermo Fisher Scientific owns PPD, one of the largest clinical CROs in the world, acquired in 2021 for $17.4 billion and now run inside its Clinical Research group. If you wanted to know how PPD's clinical workforce is faring, you might reach for Thermo Fisher's WARN record. Do not. It will mislead you, and understanding why is the whole point of this file.

A big record that is mostly not the CRO

On the aggregated public filings, Thermo Fisher has submitted 47 WARN notices covering about 2,345 people since 2002. Recent activity is real: 173 people in Carlsbad, California in early 2026, dozens more in Carlsbad through 2025, cuts in Orlando and Cerritos, and rounds in Massachusetts and Florida before that. It looks like a company doing significant cutting, and it is.

But read the locations. Carlsbad, Alachua, Salt Lake City, Auburn, Cambridge, Plainville. These are instruments, life-sciences manufacturing, and bioproduction sites. Thermo Fisher is a roughly $40-billion conglomerate whose businesses run from lab equipment to viral vector manufacturing. The clinical CRO, legacy PPD, is one slice of it, and its people mostly do not sit in the buildings that file WARN notices.

Where the clinical cuts went

The clinical cuts at PPD have been widely reported through employee channels and industry press: reductions across data management, clinical operations, and project delivery, described as rolling RIFs rather than single-site closures. That is precisely the shape that does not trip a WARN threshold. A CRO workforce is remote and distributed, so a reduction of a few people per location across many states and countries can be large in total and invisible in the public record.

So Thermo Fisher's thick WARN record is the manufacturing and instruments side, and PPD's clinical reductions are the part you cannot see in it. The company can be cutting hundreds of clinical staff while its WARN filings are all about plants and labs.

Why this matters when you read any conglomerate

The lesson generalizes. When a clinical CRO is owned inside a larger company, and several now are, its health is buried in a corporate WARN record dominated by other businesses. You cannot separate the clinical signal from the manufacturing noise by reading the filings. The same caution applies to any diversified parent: the public layoff record reflects the physical footprint, not the remote knowledge workforce, and it lumps unrelated divisions together.

For someone evaluating PPD as an employer, this means the usual public signals are close to useless, and you are left with the softer ones: hiring freezes, program cancellations, and what current staff actually report. The absence of PPD-labeled WARN filings tells you nothing reassuring.

What only the workforce knows

The real state of PPD's clinical teams, which functions were cut, how deep, and what it did to workloads for the people who remained, exists in exactly one place: the people who were there. No filing captures it. No parent-company disclosure breaks it out.

If you work in Thermo Fisher's clinical research group or left in one of the reported reductions, that is information the public record structurally cannot hold. Share what you can, without naming individuals, and add your compensation datapoint to the survey. On a conglomerate, the workforce is the only honest source there is.